{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:39:48Z","timestamp":1777934388223,"version":"3.51.4"},"reference-count":47,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T00:00:00Z","timestamp":1560297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Chronic lymphocytic leukemia is one of the most common lymphoid malignancies. Often treatment modalities are tailored to individual patients based on age, presence of comorbidities and cytogenetics. The advent of ibrutinib has significantly changed the management of the disease in all patient groups and has had the largest impact on clinical practice to date. Over the last 15 years, a series of trials have established that chemoimmunotherapy improves both progression-free survival and overall survival compared to chemotherapy alone. Despite its proven role, efficacy of ibrutinib has not been well established in young, fit patients and in comparison with standard care and as combination therapy with other agents such as venetoclax. New data have strengthened the role of ibrutinib in the front-line setting and establish its place in therapy. In addition, combination therapies are geared to achieve negative minimal residual disease and allow patients to potentially be off of therapy. The management of this leukemia has extensively changed over the past years, and this review article will aim to highlight key trials that have changed practice and led to guideline updates. It is not unlikely that treatment modalities will continue to improve in light of new data.<\/jats:p>","DOI":"10.1177\/1078155219853030","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T02:34:14Z","timestamp":1560393254000},"page":"146-155","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Updates in the management of chronic lymphocytic leukemia\/small lymphocytic leukemia"],"prefix":"10.1177","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3467-9336","authenticated-orcid":false,"given":"Kirollos S","family":"Hanna","sequence":"first","affiliation":[{"name":"Mayo Clinic College of Medicine, Mayo Clinic & University of Minnesota Medical Center, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,6,12]]},"reference":[{"key":"bibr1-1078155219853030","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21551"},{"key":"bibr2-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.4508"},{"key":"bibr3-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041720"},{"key":"bibr4-1078155219853030","unstructured":"National comprehensive cancer network clinical practice guidelines in oncology. Chronic lymphocytic leukemia\/small cell lymphoma v4.2019, www.Nccn.Org (accessed 17 March 2019)."},{"key":"bibr5-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07711.x"},{"key":"bibr6-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.2704"},{"key":"bibr7-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0892"},{"key":"bibr8-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.2.635"},{"key":"bibr9-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3277"},{"key":"bibr10-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.7.1795.1795"},{"key":"bibr11-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115717"},{"key":"bibr12-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb08169.x"},{"key":"bibr13-1078155219853030","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues 4th ed","volume":"2","author":"Swerdlow SH","year":"2008"},{"key":"bibr14-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"bibr15-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V46.2.219.219"},{"key":"bibr16-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"key":"bibr17-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.6.1840"},{"key":"bibr18-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.6.5667"},{"key":"bibr19-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3009"},{"key":"bibr20-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"bibr21-1078155219853030","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.025338"},{"key":"bibr22-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23993"},{"key":"bibr23-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw419"},{"key":"bibr24-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29566"},{"key":"bibr25-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1701"},{"key":"bibr26-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"bibr27-1078155219853030","first-page":"128","author":"Barr P","year":"2016","journal-title":"Blood"},{"key":"bibr28-1078155219853030","first-page":"132","author":"Woyach JA","year":"2018","journal-title":"Blood"},{"key":"bibr29-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30171-0"},{"key":"bibr30-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1400376"},{"key":"bibr31-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.175"},{"key":"bibr32-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"bibr33-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"bibr34-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71182-9"},{"key":"bibr35-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820910"},{"key":"bibr36-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30212-1"},{"key":"bibr37-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5"},{"key":"bibr38-1078155219853030","first-page":"132","author":"Shanafelt TD","year":"2018","journal-title":"Blood"},{"key":"bibr39-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"bibr40-1078155219853030","unstructured":"Genentech submits supplemental new drug application to FDA for venclexta plus gazyva for previously untreated chronic lymphocytic leukemia with co-existing medical conditions. Genentech (Roche), https:\/\/bit.ly\/2C9as21 (accessed 18 March 2019)."},{"key":"bibr41-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7502"},{"key":"bibr42-1078155219853030","doi-asserted-by":"crossref","unstructured":"Rogers KA, Huang Y, Ruppert AS, et\u00a0al. Phase 2 study of combination obinutuzumab, ibrutinib, and venetoclax in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia. In:\n                      Proceedings from the 2018 ASH annual meeting\n                      , San Diego, California, 1\u20134 December 2018. Abstract 693.","DOI":"10.1182\/blood-2018-99-114169"},{"key":"bibr43-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7512"},{"key":"bibr44-1078155219853030","doi-asserted-by":"crossref","unstructured":"Seymour J, Kipps T, Eichhorst B, et\u00a0al. MURANO Trial establishes feasibility of time-limited venetoclax-rituximab (VenR) combination therapy in relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL) In:\n                      Proceedings from the 2018 ASH annual meeting\n                      , San Diego, California, 1\u20134 December 2018. Abstract 184.","DOI":"10.1182\/blood-2018-184"},{"key":"bibr45-1078155219853030","first-page":"130","author":"Byrd JC","year":"2017","journal-title":"Blood"},{"key":"bibr46-1078155219853030","first-page":"128","author":"Awan FT","year":"2016","journal-title":"Blood"},{"key":"bibr47-1078155219853030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-05-850461"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219853030","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155219853030","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155219853030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:21:15Z","timestamp":1777688475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155219853030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,12]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1177\/1078155219853030"],"URL":"https:\/\/doi.org\/10.1177\/1078155219853030","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,12]]}}}